LIFE Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$27.43median target· current $20.42 (+34.3%)9 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
46 articles · sorted by datePage 1 of 3 · 46 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.71161.6% YoY
Profit margin-22.1%FINANCIAL SERVICES
Market cap$1.94BSmall cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.92
- P/S (TTM)
- 4.00
- EV/EBITDA
- 17.25
Profitability & growth
- ROE (TTM)
- -29.1%
- Operating margin
- -84.6%
- Revenue growth YoY
- 103.5%
- Dividend yield
- —
- Beta
- —
Last earnings
May 6, 2026 · Estimate $0.47 · Reported $0.38
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Ethos Technologies Inc. Class A Common Stock
Company profileaTyr Pharma, Inc., a clinical-stage biotherapeutics company, is dedicated to the discovery and development of drugs based on new immune pathways in the United States. The company is headquartered in San Diego, California.
Classification
- Sector
- Financial Services
- Industry
- Insurance Brokers
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 90 NEW MONTGOMERY STREET, SAN FRANCISCO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$1.94B
Shares outstanding$30.9M
52W high$32.50
52W low$9.45
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent